{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:34:55Z","timestamp":1790969695243,"version":"4.1.0"},"reference-count":82,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Moving toward a goal-directed-treatment strategy in osteoporosis necessitates considering the opportunities and challenges associated with transitions in osteoporosis therapy.<\/jats:p>\n                  <jats:p>Some transitions are straightforward; transition from bone anabolic treatment to antiresorptives maintains or further improves the bone mineral density (BMD) increase and the antifracture effect obtained during treatment with a bone anabolic. Transitions from one antiresorptive to another are also, in most cases, safe and may lead to further increases in BMD if the transition is from an oral antiresorptive to a parentally administrated antiresorptive, such as zoledronate or denosumab.<\/jats:p>\n                  <jats:p>However, challenges arise when transitioning from antiresorptives to bone anabolic treatment, as the anabolic effect will be blunted compared to the effect seen in treatment-na\u00efve patients, and transitions involving discontinuation of denosumab after more than 2 to 3 years of treatment.<\/jats:p>\n                  <jats:p>Sequential treatment of osteoporosis is needed for many patients to prevent fractures and obtain BMD levels associated with an acceptable fracture risk. While not all treatment transitions are optimal, the majority are safe, except for transitioning from denosumab to a bone anabolic agent or discontinuation of denosumab without appropriate follow-up treatment. These specific transitions should be avoided.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf614","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T12:54:50Z","timestamp":1763297690000},"page":"e577-e585","source":"Crossref","is-referenced-by-count":3,"title":["Approach to the Patient - Transitions in Osteoporosis Therapy"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"Bente L","family":"Langdahl","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, DK-8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmarklinical Medicine ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6740-3072","authenticated-orcid":false,"given":"Natasha A","family":"Laursen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, DK-8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmarklinical Medicine ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8557-6396","authenticated-orcid":false,"given":"Vivi","family":"M\u00e4kinen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, DK-8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmarklinical Medicine ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-3523","authenticated-orcid":false,"given":"Torben","family":"Harsl\u00f8f","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, DK-8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmarklinical Medicine ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7252-8128","authenticated-orcid":false,"given":"Anne Sophie","family":"S\u00f8lling","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital, DK-8200 Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"1","key":"2026012101520805400_dgaf614-B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women\u201d","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026012101520805400_dgaf614-B2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026012101520805400_dgaf614-B3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2213-8587(24)00092-5","article-title":"Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE","volume":"12","author":"Black","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2026012101520805400_dgaf614-B4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026012101520805400_dgaf614-B5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jc.2012-3680","article-title":"Treat-to-target for osteoporosis: is now the time?","volume":"98","author":"Lewiecki","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026012101520805400_dgaf614-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026012101520805400_dgaf614-B7","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2026012101520805400_dgaf614-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical Endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"5","key":"2026012101520805400_dgaf614-B9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026012101520805400_dgaf614-B10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2026012101520805400_dgaf614-B11","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2026012101520805400_dgaf614-B12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2026012101520805400_dgaf614-B13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"19","key":"2026012101520805400_dgaf614-B14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"2026012101520805400_dgaf614-B15","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026012101520805400_dgaf614-B16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"18","key":"2026012101520805400_dgaf614-B17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"14","key":"2026012101520805400_dgaf614-B18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"2026012101520805400_dgaf614-B19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"2026012101520805400_dgaf614-B20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12703\/r\/10-44","article-title":"Anabolic treatments for osteoporosis in postmenopausal women","volume":"10","author":"Hassan","year":"2021","journal-title":"Fac Rev"},{"issue":"1","key":"2026012101520805400_dgaf614-B21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"issue":"15","key":"2026012101520805400_dgaf614-B22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2026012101520805400_dgaf614-B23","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","article-title":"A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab","volume":"31","author":"McClung","year":"2020","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026012101520805400_dgaf614-B24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2026012101520805400_dgaf614-B25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00198-022-06570-0","article-title":"Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese osteoporosis intervention trial-05","volume":"34","author":"Mori","year":"2023","journal-title":"Osteoporos Int"},{"key":"2026012101520805400_dgaf614-B26","doi-asserted-by":"crossref","first-page":"20420188231213640","DOI":"10.1177\/20420188231213639","article-title":"Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone","volume":"14","author":"Giveon","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"2026012101520805400_dgaf614-B27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2026012101520805400_dgaf614-B28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/imj.70061","article-title":"First-line treatment of osteoporosis with osteoanabolic therapy: a new opportunity","volume":"55","author":"Aleksova","year":"2025","journal-title":"Intern Med J"},{"issue":"2","key":"2026012101520805400_dgaf614-B29","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.beem.2022.101623","article-title":"The effect of osteoporosis treatment on bone mass","volume":"36","author":"Appelman-Dijkstra","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026012101520805400_dgaf614-B30","doi-asserted-by":"crossref","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","article-title":"Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches","volume":"139","author":"Langdahl","year":"2020","journal-title":"Bone"},{"issue":"8","key":"2026012101520805400_dgaf614-B31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026012101520805400_dgaf614-B32","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026012101520805400_dgaf614-B33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026012101520805400_dgaf614-B34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","article-title":"Clinical experience with denosumab discontinuation","volume":"36","author":"Laursen","year":"2025","journal-title":"Osteoporos Int"},{"issue":"7","key":"2026012101520805400_dgaf614-B35","doi-asserted-by":"crossref","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"key":"2026012101520805400_dgaf614-B36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/PPA.S95634","article-title":"Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis","volume":"10","author":"Calabria","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"2026012101520805400_dgaf614-B37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"2026012101520805400_dgaf614-B38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334)","volume":"86","author":"Jolette","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"issue":"12","key":"2026012101520805400_dgaf614-B39","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"},{"issue":"8","key":"2026012101520805400_dgaf614-B40","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00198-022-06386-y","article-title":"Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis","volume":"33","author":"Ebina","year":"2022","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026012101520805400_dgaf614-B41","doi-asserted-by":"crossref","first-page":"ziae131","DOI":"10.1093\/jbmrpl\/ziae131","article-title":"Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab","volume":"8","author":"Kobayakawa","year":"2024","journal-title":"JBMR Plus"},{"issue":"10102","key":"2026012101520805400_dgaf614-B42","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"2026012101520805400_dgaf614-B43","doi-asserted-by":"crossref","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"10","key":"2026012101520805400_dgaf614-B44","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026012101520805400_dgaf614-B45","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026012101520805400_dgaf614-B46","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026012101520805400_dgaf614-B47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026012101520805400_dgaf614-B48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026012101520805400_dgaf614-B49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","article-title":"Pharmacokinetics of alendronate","volume":"36","author":"Porras","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2026012101520805400_dgaf614-B50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus"},{"issue":"9999","key":"2026012101520805400_dgaf614-B51","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"2026012101520805400_dgaf614-B52","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.3198","article-title":"Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-switch HR-pQCT study","volume":"32","author":"Tsai","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026012101520805400_dgaf614-B53","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026012101520805400_dgaf614-B54","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0731-7085(02)00218-2","article-title":"Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine","volume":"30","author":"Legay","year":"2002","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"2026012101520805400_dgaf614-B55","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5\u2005mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"issue":"1","key":"2026012101520805400_dgaf614-B56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026012101520805400_dgaf614-B57","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2026012101520805400_dgaf614-B58","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"issue":"8","key":"2026012101520805400_dgaf614-B59","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026012101520805400_dgaf614-B60","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2004-2212","article-title":"The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis","volume":"91","author":"Michalsk\u00e1","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026012101520805400_dgaf614-B61","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","volume":"26","author":"Anastasilakis","year":"2015","journal-title":"Osteoporos Int"},{"issue":"5","key":"2026012101520805400_dgaf614-B62","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"24","key":"2026012101520805400_dgaf614-B63","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"2026012101520805400_dgaf614-B64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026012101520805400_dgaf614-B65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 years of age","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"2026012101520805400_dgaf614-B66","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012101520805400_dgaf614-B67","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026012101520805400_dgaf614-B68","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026012101520805400_dgaf614-B69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"2026012101520805400_dgaf614-B70","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026012101520805400_dgaf614-B71","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026012101520805400_dgaf614-B72","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026012101520805400_dgaf614-B73","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026012101520805400_dgaf614-B74","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"S\u00f8lling","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026012101520805400_dgaf614-B75","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026012101520805400_dgaf614-B76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"(1)","key":"2026012101520805400_dgaf614-B77","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026012101520805400_dgaf614-B78","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026012101520805400_dgaf614-B79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026012101520805400_dgaf614-B80","doi-asserted-by":"crossref","first-page":"e10731","DOI":"10.1002\/jbm4.10731","article-title":"Discontinuation of denosumab: gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine","volume":"7","author":"Laroche","year":"2023","journal-title":"JBMR Plus"},{"issue":"3","key":"2026012101520805400_dgaf614-B81","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","article-title":"Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60\u2005mg dose: a prospective observational study","volume":"80","author":"Khan","year":"2023","journal-title":"Endocrine"},{"issue":"7","key":"2026012101520805400_dgaf614-B82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf614\/65353788\/dgaf614.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf614\/65353788\/dgaf614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf614\/65353788\/dgaf614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:52:25Z","timestamp":1768978345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/2\/e577\/8324892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":82,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,17]]},"published-print":{"date-parts":[[2026,1,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf614","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,17]]}}}